TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1479003

Group type: EXPERIMENTAL
Intervention: 3.75 mg D‐Trp‐6‐luteinizing hormone-releasing hormone (LHRH)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 1.87 mg D‐Trp‐6‐luteinizing hormone-releasing hormone (LHRH)
Number of subjects: 20
Study: 2410686

Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trimazosin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prazosin and Doxazosin
Number of subjects: 0
Study: 30832454

Group type: EXPERIMENTAL
Intervention: Tai Chi Chuan (TCC)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Core Stability Training (CST)
Number of subjects: 43
Study: 29671368

Group type: EXPERIMENTAL
Intervention: Topical human amniotic membrane-mesenchymal stem cell-conditioned medium (hAMMSC-CM) + vitamin E
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topical human amniotic membrane-mesenchymal stem cell-conditioned medium (hAMMSC-CM) + vitamin C
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topical human amniotic membrane-mesenchymal stem cell-conditioned medium (hAMMSC-CM) alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 26359346

Group type: EXPERIMENTAL
Intervention: Multicomponent physical activity intervention
Number of subjects: 1150
Study: 24521245

Group type: EXPERIMENTAL
Intervention: Lixisenatide (LIXI) 20 µg
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study: 22468806

Group type: EXPERIMENTAL
Intervention: Pemetrexed 1,800 mg/m2 plus cyclophosphamide 600 mg/m2
Number of subjects: 103

Group type: COMPARATOR
Intervention: Pemetrexed 600 mg/m2 plus cyclophosphamide 600 mg/m2
Number of subjects: 103
Study: 20230403

Group type: EXPERIMENTAL
Intervention: Eculizumab
Number of subjects: 73
Study: 18339046

Group type: EXPERIMENTAL
Intervention: Amber tinted contact lens
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Grey-green tinted contact lens
Number of subjects: 13

Group type: COMPARATOR
Intervention: Clear contact lens (Optima 38)
Number of subjects: 13
Study: 15655124

Group type: EXPERIMENTAL
Intervention: Lisinopril with or without hydrochlorothiazide, or nifedipine or an angiotensin receptor blocker for uncontrolled hypertensive subjects
Number of subjects: 51

Group type: COMPARATOR
Intervention: Observation (no treatment) for normotensive and treated hypertensive subjects
Number of subjects: 51
Study: 12011292

Group type: EXPERIMENTAL
Intervention: Interferon-beta1a
Number of subjects: 0
Study: 9861443

Group type: EXPERIMENTAL
Intervention: Greenselect (free form of catechins)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Greenselect Phytosome (phospholipid complex form)
Number of subjects: 0
Study: 7796586

Group type: EXPERIMENTAL
Intervention: Oral monophasic contraceptive (ethinylestradiol 20 micrograms + desogestrel 0.150 mg)
Number of subjects: 200

Group type: COMPARATOR
Intervention: No treatment (Control Group B)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 200
Study: 2356085

Group type: EXPERIMENTAL
Intervention: Prophylactic diflunisal (two tablets immediately at the conclusion of the visit, then four tablets to be taken in the schedule of one every 8 to 12 hours for pain if needed)
Number of subjects: 100

Group type: COMPARATOR
Intervention: On-demand diflunisal (same dosage schedule; pills to be taken only if needed)
Number of subjects: 100
Study: 517519

Group type: EXPERIMENTAL
Intervention: 47,XXY men
Number of subjects: 78

Group type: COMPARATOR
Intervention: Matched controls with 46,XY
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: 47,XYY men
Number of subjects: 78
Study: 31334393

Group type: EXPERIMENTAL
Intervention: Slow-stroke back massage (n=30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (n=30)
Number of subjects: 60
Study: 28916142

Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 26689281

Group type: EXPERIMENTAL
Intervention: Pre-quit nicotine patch treatment (two weeks of patch treatment prior to a quit day, followed by 10 weeks post-quit treatment)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Varenicline (starting two weeks prior to quit day followed by 10 weeks post-quit)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Standard patch treatment (10 weeks of patch starting from a designated quit day)
Number of subjects: 216
Study: 24170536

Group type: EXPERIMENTAL
Intervention: Rad technique
Number of subjects: 62

Group type: COMPARATOR
Intervention: Conventional technique
Number of subjects: 62
Study: 21380937

Group type: EXPERIMENTAL
Intervention: Naltrexone (4.5 mg daily)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 18326591

Group type: EXPERIMENTAL
Intervention: DHA (400 mg/d)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135
Study: 17142642

Group type: EXPERIMENTAL
Intervention: Aquatic physical therapy for 6 weeks
Number of subjects: 71

Group type: COMPARATOR
Intervention: No aquatic physical therapy (control)
Number of subjects: 71
Study: 12945024

Group type: EXPERIMENTAL
Intervention: Continuous 3-in-1 block
Number of subjects: 44

Group type: COMPARATOR
Intervention: Continuous fascia iliaca compartment block
Number of subjects: 44
Study: 11026748

Group type: EXPERIMENTAL
Intervention: 120 mg Ginkgo biloba
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 240 mg Ginkgo biloba
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 360 mg Ginkgo biloba
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 9062542

Group type: EXPERIMENTAL
Intervention: Low-dose beta-carotene (0.5 mg/d) for days 1-60
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Carotenoid complex from vegetables rich in carotenoids on days 101-120
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo for days 1-60
Number of subjects: 9
Study: 1306851

Group type: EXPERIMENTAL
Intervention: 50/50 EE (50 micrograms EE + 125 micrograms desogestrel)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 40/30 EE (40 micrograms EE + 25 micrograms desogestrel)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 50/50 EE
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 40/30 EE
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control values (not specified)
Number of subjects: 0
Study: 3000176

Group type: EXPERIMENTAL
Intervention: Sorbinil (250 mg daily for 6 weeks)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 30280130

Group type: COMPARATOR
Intervention: Limited discectomy
Number of subjects: 278
Study: 27649561

Group type: EXPERIMENTAL
Intervention: Artemether-Lumefantrine (AL)
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-Piperaquine (DP)
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Artemether-Lumefantrine (AL) and Dihydroartemisinin-Piperaquine (DP)
Number of subjects: 312
Study: 23615480

Group type: EXPERIMENTAL
Intervention: Static 5-minute stretching
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control (no stretching)
Number of subjects: 19
Study: 22327755

Group type: EXPERIMENTAL
Intervention: Home-based cardiac rehabilitation (n=28)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Standard hospital treatment (n=21)
Number of subjects: 49
Study: 20189552

Group type: EXPERIMENTAL
Intervention: Informative adjective-noun phrases (e.g. blue car)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control trials (uninformative adjective-noun phrases)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Informative adjective-noun phrases
Number of subjects: 30
Study: 18341756

Group type: EXPERIMENTAL
Intervention: Milk fermented with Lactobacillus casei
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 104
Study: 15653967

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS) exposure
Number of subjects: 17842

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate
Number of subjects: 17842

Group type: EXPERIMENTAL
Intervention: Other ICS
Number of subjects: 17842

Group type: EXPERIMENTAL
Intervention: ICS exposure among patients with COPD only
Number of subjects: 17842
Study: 12204459

Group type: EXPERIMENTAL
Intervention: Ventilation-compression ratio 1:5
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Ventilation-compression ratio 2:15
Number of subjects: 14

Group type: COMPARATOR
Intervention: Both ratios (1:5 and 2:15)
Number of subjects: 14
Study: 10325849

Group type: EXPERIMENTAL
Intervention: Endovascular surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional surgery
Number of subjects: 0
Study: 8953203

Group type: EXPERIMENTAL
Intervention: Insulin treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral treatment (sulfonylurea)
Number of subjects: 0
Study: 1672588

Group type: EXPERIMENTAL
Intervention: Intermittent medication (given only when the patient shows early signs of relapse)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Moderate doses of maintenance medication
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Intermittent medication
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Early intervention strategy
Number of subjects: 101
Study: 7138951

Group type: EXPERIMENTAL
Intervention: Instructions to decrease HR plus continuous negative (failure) binary feedback
Number of subjects: 16

Group type: COMPARATOR
Intervention: Instructions to decrease HR only
Number of subjects: 16
Study: 31281931

Group type: EXPERIMENTAL
Intervention: CRE colonisation and infections
Number of subjects: 2875

Group type: EXPERIMENTAL
Intervention: Klebsiella pneumoniae
Number of subjects: 2875

Group type: EXPERIMENTAL
Intervention: KPC-2-producing bacteria
Number of subjects: 2875

Group type: COMPARATOR
Intervention: No underlying conditions
Number of subjects: 2875

Group type: COMPARATOR
Intervention: Pulmonary diseases
Number of subjects: 2875

Group type: COMPARATOR
Intervention: No antibiotics used prior to culture within 30 days
Number of subjects: 2875
Study: 28304242

Group type: EXPERIMENTAL
Intervention: Bococizumab (150 mg subcutaneously every 2 weeks)
Number of subjects: 27438

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27438

Group type: EXPERIMENTAL
Intervention: Bococizumab
Number of subjects: 27438
Study: 25651842

Group type: EXPERIMENTAL
Intervention: Early antiretroviral therapy (ART) initiation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Deferred ART initiation
Number of subjects: 0
Study: 23777411

Group type: EXPERIMENTAL
Intervention: Extraction of one deciduous canine
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (contralateral side, no extraction)
Number of subjects: 24
Study: 22908169

Group type: EXPERIMENTAL
Intervention: 1,500 mg piperacillin
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 3,000 mg piperacillin
Number of subjects: 10

Group type: COMPARATOR
Intervention: High-dose short-term infusions (6 g every 8 h)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Low-dose continuous infusions (6 g/day)
Number of subjects: 10
Study: 19126633

Group type: EXPERIMENTAL
Intervention: Immediate intervention (start of cancer treatment)
Number of subjects: 465

Group type: EXPERIMENTAL
Intervention: Delayed intervention (8 weeks after starting treatment)
Number of subjects: 465

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 465

Group type: EXPERIMENTAL
Intervention: Immediate intervention (for high-risk patients)
Number of subjects: 465

Group type: COMPARATOR
Intervention: Usual care (for high-risk patients)
Number of subjects: 465

Group type: EXPERIMENTAL
Intervention: Immediate intervention (for low-risk patients)
Number of subjects: 465

Group type: COMPARATOR
Intervention: Usual care (for low-risk patients)
Number of subjects: 465
Study: 17407391

Group type: EXPERIMENTAL
Intervention: Subcutaneous glatiramer acetate (SC GA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intramuscular interferon beta-1a (IM IFNbeta‐1a)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subcutaneous interferon beta-1a (SC IFNbeta‐1a)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subcutaneous interferon beta-1b (SC IFNbeta‐1b)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Symptom management alone
Number of subjects: 0
Study: 15357164

Group type: EXPERIMENTAL
Intervention: Povidone-iodine ointment and gauze dressings
Number of subjects: 0

Group type: COMPARATOR
Intervention: Transparent dressings alone (Control)
Number of subjects: 0
Study: 11167352

Group type: EXPERIMENTAL
Intervention: 5.0 mg cetirizine
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 2.5 mg levocetirizine
Number of subjects: 18

Group type: COMPARATOR
Intervention: 2.5 mg ucb 28557
Number of subjects: 18
Study: 9745994

Group type: EXPERIMENTAL
Intervention: Profiled Hemodialysis (PHD)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Standard Hemodialysis (SHD)
Number of subjects: 12
Study: 7833105

Group type: EXPERIMENTAL
Intervention: CEV (cyclophosphamide 1000 mg/m2 i.v., epirubicin 70 mg/m2 i.v., vincristine 1.2 mg/m2 i.v., every 3 weeks)
Number of subjects: 139

Group type: COMPARATOR
Intervention: PE (cisplatin 20 mg/m2 i.v. and etoposide 75 mg/m2 i.v. for 5 consecutive days, every 3 weeks)
Number of subjects: 139
Study: 3207526

Group type: EXPERIMENTAL
Intervention: Atracurium
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Vecuronium
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Pancuronium
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Alcuronium
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Tubocurarine
Number of subjects: 30
Study: 29177605

Group type: EXPERIMENTAL
Intervention: IHC4 + Clinical PathIES score
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: IHC4 score alone
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: Clinical score (C) based on age, grade, tumour size and nodal status
Number of subjects: 430
Study: 28051270

Group type: EXPERIMENTAL
Intervention: Retroperitoneal laparoscopic partial dissection of adipose renal capsule plus ligation of renal pedicle lymphatic vessels (Group A)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Retroperitoneal laparoscopic complete dissection of adipose renal capsule plus ligation of renal pedicle lymphatic vessels (Group B)
Number of subjects: 38
Study: 26149996

Group type: EXPERIMENTAL
Intervention: Lopinavir (LPV) treatment during pregnancy
Number of subjects: 208
Study: 23957383

Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg
Number of subjects: 338

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: Rabeprazole 10 mg
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: Rabeprazole 40 mg
Number of subjects: 338
Study: 21348538

Group type: EXPERIMENTAL
Intervention: Saxagliptin 10 mg (Onglyza™)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Saxagliptin 5 mg (2.5 mg orally once daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Saxagliptin
Number of subjects: 0
Study: 18469231

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 47
Study: 16950285

Group type: EXPERIMENTAL
Intervention: Farm exposure in early life
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: CD14-159TT genotype
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Combination of farm exposure and CD14-159TT genotype
Number of subjects: 600
Study: 15062149

Group type: EXPERIMENTAL
Intervention: 20 Gy EBRT
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: 44 Gy EBRT
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Pd‐103 implantation
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 91
Study: 11467759

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 51
Study: 9575675

Group type: EXPERIMENTAL
Intervention: Longer length alleles of the PEM gene in severe acne patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0

Group type: COMPARATOR
Intervention: Atopic dermatitis patients
Number of subjects: 0
Study: 7827905

Group type: EXPERIMENTAL
Intervention: Preoperative mechanical bowel preparation (group 1)
Number of subjects: 149

Group type: COMPARATOR
Intervention: No mechanical bowel preparation (group 2)
Number of subjects: 149
Study: 3168339

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium chloride (10 mmol in 100 ml isotonic sodium chloride)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo (isotonic sodium chloride only)
Number of subjects: 9
Study: 30929643

Group type: EXPERIMENTAL
Intervention: Teaching problem solving skills over six sessions of two hours each to the intervention group.
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Teaching problem solving skills to the intervention group.
Number of subjects: 90
Study: 29026903

Group type: EXPERIMENTAL
Intervention: 30 g freeze dried blueberry powder (WBB)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 25335119

Group type: EXPERIMENTAL
Intervention: Ospemifene 60 mg/day
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study: 23446667

Group type: EXPERIMENTAL
Intervention: Colonoscopy
Number of subjects: 492

Group type: EXPERIMENTAL
Intervention: CTC
Number of subjects: 492

Group type: COMPARATOR
Intervention: Colonoscopy and CTC
Number of subjects: 492
Study: 22088858

Group type: EXPERIMENTAL
Intervention: 10 mg/day ezetimibe/simvastatin combination therapy
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 20 mg/day atorvastatin
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 10 mg/day rosuvastatin
Number of subjects: 150
Study: 19442725

Group type: EXPERIMENTAL
Intervention: Lactolycopene supplementation for 12 weeks
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 16355341

Group type: EXPERIMENTAL
Intervention: Atazanavir, 400 mg once daily plus efavirenz placebo
Number of subjects: 211

Group type: COMPARATOR
Intervention: Efavirenz, 600 mg once daily plus atazanavir placebo
Number of subjects: 211
Study: 15053688

Group type: EXPERIMENTAL
Intervention: Differentiation of pitch durations within tone sequences
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hierarchical organization of pitch distributions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Differentiation of tonic from nontonic pitches
Number of subjects: 0
Study: 10739509

Group type: EXPERIMENTAL
Intervention: Raloxifene 150 mg/d
Number of subjects: 136

Group type: COMPARATOR
Intervention: Continuous-combined hormone replacement therapy (conjugated equine estrogens 0.625 mg/d with medroxyprogesterone acetate 2.5 mg/d)
Number of subjects: 136
Study: 9059215

Group type: EXPERIMENTAL
Intervention: Desflurane (1 MAC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Isoflurane (1 MAC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Desflurane (1 MAC) and Isoflurane (1 MAC)
Number of subjects: 0
Study: 7801591

Group type: EXPERIMENTAL
Intervention: Nonionic contrast media (CM)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Urografin (ionic CM)
Number of subjects: 90
Study: 31912801

Group type: EXPERIMENTAL
Intervention: Trifluridine/tipiracil (FTD/TPI)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study: 31001264

Group type: EXPERIMENTAL
Intervention: SjCTPI bovine vaccine (prime-boost regimen)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Human mass chemotherapy (praziquantel)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Mollusciciding
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: SjCTPI bovine vaccine
Number of subjects: 12
Study: 27662321

Group type: EXPERIMENTAL
Intervention: Total Sleep Time (TST)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Sleep Efficiency (SE)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Number of Awakenings
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Functional Disability (ADCS-ADL scores)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Alzheimer's Disease Severity
Number of subjects: 208
Study: 25538277

Group type: EXPERIMENTAL
Intervention: H3N2c cell‐culture‐derived vaccine with MF59 adjuvant
Number of subjects: 627

Group type: COMPARATOR
Intervention: H3N2c cell‐culture‐derived vaccine without MF59 adjuvant
Number of subjects: 627

Group type: EXPERIMENTAL
Intervention: 7.5 µg + 0.25 mL MF59
Number of subjects: 627

Group type: EXPERIMENTAL
Intervention: MF59‐adjuvanted H3N2c vaccines
Number of subjects: 627
Study: 23612700

Group type: EXPERIMENTAL
Intervention: Primary ligation of the pulmonary artery (group A)
Number of subjects: 385

Group type: COMPARATOR
Intervention: Primary ligation of the pulmonary vein (group V)
Number of subjects: 385
Study: 22111718

Group type: EXPERIMENTAL
Intervention: Daily low-dose budesonide (0.5 mg nightly)
Number of subjects: 278

Group type: COMPARATOR
Intervention: Intermittent high-dose budesonide (1 mg twice daily for 7 days during respiratory illness)
Number of subjects: 278
Study: 18953855

Group type: EXPERIMENTAL
Intervention: Intraoperative facial nerve (NF) monitoring (Group FN)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Monitoring of multiple nerves (trigeminal, glossopharyngeal, accessory, hypoglossal) (Group MN)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Partial neuromuscular relaxation maintained at train of four stimulation (TOF)=3 by continuous vencronium infusion
Number of subjects: 70
Study: 16409339

Group type: EXPERIMENTAL
Intervention: 150 microg morphine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 60
Study: 12932091

Group type: EXPERIMENTAL
Intervention: Chloroquine plus artesunate
Number of subjects: 536

Group type: COMPARATOR
Intervention: Chloroquine monotherapy
Number of subjects: 536
Study: 11421382

Group type: EXPERIMENTAL
Intervention: HT-ETIG
Number of subjects: 134

Group type: COMPARATOR
Intervention: ETIG
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: HT-ETIG and ETIG
Number of subjects: 134
Study: 9273226

Group type: EXPERIMENTAL
Intervention: Interleukin-6 (IL-6) and interleukin-8 (IL-8) measured in bronchoalveolar lavage fluid
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (14 subjects)
Number of subjects: 32
Study: 1515386

Group type: EXPERIMENTAL
Intervention: 17.5 ml mepivacaine
Number of subjects: 16

Group type: COMPARATOR
Intervention: 17.5 ml bupivacaine
Number of subjects: 16